Question of the Week - January 16th
Semaglutide (Ozempic) is a newly approved GLP-1 Receptor Agonist with a few unique features. Which of the following statements is true about Semaglutide (Ozempic)?
A. It is available as an oral medication or injectable
B. It reduces A1c less than other GLP-1 RAs
C. It is associated with greater weight loss than other GLP-1 RAs
D. It can be administered via pump
This form was created inside of Diabetes Educational Services.
Terms of Service